Abstract: The present invention relates to a metal powder including 0.1?C?0.4 mass %, 0.005?Si?1.5 mass %, 0.3?Mn?8.0 mass %, 2.0?Cr?15.0 mass %, 2.0?Ni?10.0 mass %, 0.1?Mo?3.0 mass %, 0.1?V?2.0 mass %, 0.010?N?0.200 mass %, and 0.01?Al?4.0 mass %, with the balance being Fe and unavoidable impurities, and satisfying the following expression (1), 10<15[C]+[Mn]+0.5[Cr]+[Ni]<20 (1), in which [C], [Mn], [Cr] and [Ni] respectively represent the contents of C, Mn, Cr and Ni by mass %.

Abstract: A powder material includes: an atomized powder of an Ni-based alloy containing inclusions, in which a number of particles of the contained inclusions is 100 particles or less per 10,000 particles of the atomized powder. The Ni-based alloy may include at least one additive element selected from Al, Ti and Nb, and the inclusions include at least one of oxide and carbonitride of the additive element.

Abstract: The present invention relates to a powder material including metal particles, in which in a mass basis cumulative particle size distribution, the metal particles have a 10% particle diameter d10 of less than 16 ?m and a 90% particle diameter d90 of more than 35 ?m and when a specific energy obtained as a value yielded by dividing a flow energy measured as an energy acting on a blade spiraling upward in the powder material by a mass of the powder material is normalized with a bulk density of the powder material, a resulting value is less than 0.47 mJ·ml/g2 and relates to a producing method for the same.

Abstract: The present invention relates to a metal powder including 0.1?C?0.4 mass %, 0.005?Si?1.5 mass %, 0.3?Mn?8.0 mass %, 2.0?Cr?15.0 mass %, 2.0?Ni?10.0 mass %, 0.1?Mo?3.0 mass %, 0.1?V?2.0 mass %, 0.010?N?0.200 mass %, and 0.01?Al?4.0 mass %, with the balance being Fe and unavoidable impurities, and satisfying the following expression (1), 10<15[C]+[Mn]+0.5[Cr]+[Ni]<20 (1), in which [C], [Mn], [Cr] and [Ni] respectively represent the contents of C, Mn, Cr and Ni by mass %.

Abstract: Provided is a novel composition. Provided is a composition for cytotoxic T cell depletion, comprising an anti-LAG-3 antibody or a binding fragment thereof having the properties described in (i) to (iii) below: (i) having in vitro ADCC activity; (ii) reducing, in a low fucose form, the number of LAG-3 positive cells in vivo; and (iii) binding to activated human T cells.

Abstract: The present invention provides a gene set for predicting the sensitivity of a cancer to a treatment with a PD-1 immune checkpoint inhibitor. More specifically, the present invention provides one or more genes selected from the group consisting of ADAM8, VCL, LEF1-AS1, TSPAN32, CTBP2, RXRA, PTGDS, ITGB1, KLRD1, RAB11FIP5, SLC4A8, NIN, GCNT2, ASB2, HNRPLL, AMPD3, SIRPG, PTPN13, MYB, ASAP1, MBOAT1, COTL1, ICOS, ST8SIA1, PASK, SGPP2, PDCD1, TBC1D4, EMP3, FAM65B, GBP1, FAM211B, PRR5, C17orf67, FAM101B and TBL1X, and a method for predicting the sensitivity of a cancer to a treatment with a PD-1 immune checkpoint inhibitor by using the genes.

Abstract: The object is to provide a combination of biomarkers which allow highly accurate discrimination of schizophrenia, and a utilization thereof. A combination of schizophrenia marker set including a combination of two or more protein molecules selected from the group consisting of trifunctional purine biosynthetic protein adenosine-3, uroporphyrinogen decarboxylase, interferon-induced GTP-binding protein Mx1, glutaredoxin-3, microtubule-associated protein RP/EB family member 1, tubulin folding cofactor B, immunoglobulin mu chain C region, and heat shock 70 kDa protein 4L is provided. In addition, a method for examining schizophrenia using the level of the marker set in a specimen as an index is provided.